{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:44:33Z","timestamp":1782492273491,"version":"3.54.5"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.farma.2022.12.010","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T23:39:58Z","timestamp":1682120398000},"page":"T69-T74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["[Translated article] Adherence and quality of life in patients with chronic lymphocytic leukemia treated with oral antineoplastic drugs"],"prefix":"10.1016","volume":"47","author":[{"given":"Mar\u00eda","family":"Ochagav\u00eda Sufrategui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"Gil Lemus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucrecia","family":"Y\u00e1\u00f1ez San Segundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Antonio","family":"Amado Diago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Barbadillo Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Mart\u00ednez Callejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Victoria","family":"Villaca\u00f1as Palomares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Valero Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.farma.2022.12.010_bb0005","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.medcli.2009.10.016","article-title":"Chronic lymphocytic leukemia","volume":"135","author":"Hern\u00e1ndez","year":"2010","journal-title":"Med Clin (Barc)"},{"issue":"6","key":"10.1016\/j.farma.2022.12.010_bb0010","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3324\/haematol.2013.096792","article-title":"Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials","volume":"99","author":"Goede","year":"2014","journal-title":"Haematologica."},{"issue":"10","key":"10.1016\/j.farma.2022.12.010_bb0015","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1172\/JCI64101","article-title":"Molecular pathogenesis of chronic lymphocytic leukemia","volume":"122","author":"Gaidano","year":"2012","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.farma.2022.12.010_bb0020","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/hon.2196","article-title":"A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia","volume":"34","author":"Gonz\u00e1lez-Gasc\u00f3n","year":"2016","journal-title":"Hematol Oncol"},{"issue":"Suppl 7","key":"10.1016\/j.farma.2022.12.010_bb0025","article-title":"Chronic lymphocytic leukemia: a short overview","volume":"19","author":"Montserrat","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.farma.2022.12.010_bb0030","series-title":"Grupo de Adherencia Terap\u00e9utica ADHEFAR de la SEFH. Lo que debes saber sobre la Adherencia al tratamiento","first-page":"5","article-title":"Definici\u00f3n e importancia de la adherencia","author":"Ibarra Barrueta","year":"2017"},{"issue":"3","key":"10.1016\/j.farma.2022.12.010_bb0035","first-page":"141","article-title":"Estudio de adhesi\u00f3n a imatinib en la leucemia mieloide cr\u00f3nica y su relaci\u00f3n con la respuesta terap\u00e9utica","volume":"40","author":"Garc\u00eda-Queiruga","year":"2016","journal-title":"Farm Hosp"},{"issue":"14","key":"10.1016\/j.farma.2022.12.010_bb0040","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.farma.2022.12.010_bb0045","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.clml.2019.09.618","article-title":"Adherence to lenalidomide in older adults with newly diagnosed multiple myeloma","volume":"20","author":"Mian","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.farma.2022.12.010_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214446","article-title":"Adherence to immunomodulatory drugs in patients with multiple myeloma","volume":"14","author":"Cransac","year":"2019","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.farma.2022.12.010_bb0055","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2141.2007.06791.x","article-title":"Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients","volume":"139","author":"Shanafelt","year":"2007","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.farma.2022.12.010_bb0060","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1007\/s11136-015-1039-y","article-title":"Quality of life of patients with chronic lymphocytic leukemia in the Netherlands: results of a longitudinal multicentre study","volume":"24","author":"Holtzer-Goor","year":"2015","journal-title":"Qual Life Res"},{"issue":"1","key":"10.1016\/j.farma.2022.12.010_bb0065","first-page":"20","article-title":"Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia","volume":"12","author":"Garner","year":"2021","journal-title":"J Adv Pract Oncol"},{"key":"10.1016\/j.farma.2022.12.010_bb0070","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1751-7176.2008.07572.x","article-title":"Predictive validity of a medication adherence measure in an outpatient setting","volume":"10","author":"Morisky","year":"2008","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.farma.2022.12.010_bb0075","series-title":"Lo que debes saber sobre la Adherencia al tratamiento","first-page":"13","article-title":"Estimaci\u00f3n de la adherencia","author":"Ibarra Barrueta","year":"2017"},{"issue":"5","key":"10.1016\/j.farma.2022.12.010_bb0080","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.farma.2022.12.010_bb0085","author":"European Organization for Research and Treatment of Cancer (EORTC) Quality of Life"},{"key":"10.1016\/j.farma.2022.12.010_bb0090","author":"EuroQol Group"},{"key":"10.1016\/j.farma.2022.12.010_bb0095","author":"Functional Assessment of Chronic Illness Therapy (FACIT) Group"},{"issue":"5","key":"10.1016\/j.farma.2022.12.010_bb0100","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1532-5415.1968.tb02103.x","article-title":"Cumulative illness rating scale","volume":"16","author":"Bernard","year":"1968","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"10.1016\/j.farma.2022.12.010_bb0105","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0025-7753(01)72040-4","article-title":"Adaptaci\u00f3n y validaci\u00f3n al castellano del cuestionario de Pfeiffer (SPMSQ) para detectar la existencia de deterioro cognitivo en personas mayores de 65 a\u00f1os","volume":"117","author":"Mart\u00ednez de la Iglesia","year":"2001","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.farma.2022.12.010_bb0110","author":"Common Terminology Criteria for Adverse Events (CTCAE) v5.0. [Internet]"},{"key":"10.1016\/j.farma.2022.12.010_bb0115","first-page":"56","article-title":"Patient adherence and persistence with oral anticancer treatment","volume":"59","author":"Ruddy","year":"2009","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.farma.2022.12.010_bb0120","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/ejh.13503","article-title":"Quality of life in patients of chronic lymphocytic leukemia using the EORTC QLQ-C30 and QLQ-CLL17 questionnaire","volume":"105","author":"Youron","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.farma.2022.12.010_bb0125","author":"European Organization for Research and Treatment of Cancer (EORTC) Quality of Life"},{"issue":"2","key":"10.1016\/j.farma.2022.12.010_bb0130","first-page":"186","article-title":"Medication adherence, health care utilization, and costs among patients initiating oral oncolytics for multiple myeloma or chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"26","author":"Dashputre","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"issue":"7","key":"10.1016\/j.farma.2022.12.010_bb0135","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.3109\/10428194.2011.649479","article-title":"Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial","volume":"53","author":"Else","year":"2012","journal-title":"Leuk Lymphoma"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634322000198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634322000198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:17:19Z","timestamp":1761106639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634322000198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1130634322000198"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2022.12.010","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Adherence and quality of life in patients with chronic lymphocytic leukemia treated with oral antineoplastic drugs","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2022.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2022.11.006","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}